Oxytocin's Effect on the Advantageous- and Disadvantageous-inequity

NCT06405737 | Completed

• 1 other identifier: UESTC-neuSCAN-88
• Study Type: interventional
• Target: 80
• Locations: 1 country
• Sites: 1

Brief Summary

The main aim of the study is to investigate whether intranasal oxytocin modulates advantageous- and disadvantageous-inequity and whether oxytocin has similar effects on them or not.

Conditions

Healthy

Keywords

advantageous inequity; disadvantageous inequity; fMRI; oxytocin

Outcome Measures

Primary Outcomes (3)

• Behavioral index: fairness rating scores

  Participants are instructed to rate their perceived levels of fairness to the allocation using a 9-point Likert scale within 4 seconds (1 = very unfair, 9 = very fair).

  45-75 minutes after treatment administration

• Behavioral index: preference rating scores

  Participants are instructed to rate their perceived levels of preference to the allocation using a 9-point Likert scale within 4 seconds (1 = not at all, 9 = very preferable).

  45-75 minutes after treatment administration

• Neural indices: fMRI-based measures of the outcome presentation stage

  Functional magnetic resonance imaging (fMRI) is employed to assess participants' blood-oxygen-level dependent signals when they are confronted with monetary allocations (advantageous-inequity, disadvantageous-inequity, and fair).

  45-75 minutes after treatment administration

Secondary Outcomes (2)

• Behavioral index: choice rate of unequal option

  45-75 minutes after treatment administration

• Neural indices: fMRI-based measures of outcome and re-decision stages

  45-75 minutes after treatment administration

Study Arms (2)

oxytocin

EXPERIMENTAL

a single dose of 24 international units (IU) of OT will be administered with 3 puffs of treatment to each nostril.

Drug: Intranasal oxytocin

placebo

EXPERIMENTAL

a single dose of 24 international units (IU) of placebo will be administered with 3 puffs of treatment to each nostril.

Drug: Intranasal placebo

Interventions

Intranasal oxytocin DRUG

Subject assigned to receive intranasal administration of oxytocin (24 IU).

oxytocin

Intranasal placebo DRUG

Subjects assigned to receive intranasal administration of placebo (24 IU).

placebo

Eligibility Criteria

• Age: 18 Years - 30 Years
• Sex: male
• Healthy Volunteers: Yes
• Age Groups: Adult (18-64)

You may qualify if:

• Healthy subjects without past or current psychiatric or neurological disorders

You may not qualify if:

• history of head injury
• pregnant,menstruating,taking oral contraceptives
• medical or psychiatric illness.
• excessive head movement (\> 3mm) during scanning

Sponsors & Collaborators

• University of Electronic Science and Technology of China: lead

Study Sites (1)

University of Electronic Science and Technology of China (UESTC)

Chengdu, Sichuan, 611731, China

Location

Study Officials

• Yao Shuxia, Dr

  University of Electronic Science and Technology of China

  PRINCIPAL INVESTIGATOR

Study Design

• Study Type: interventional
• Phase: not applicable
• Allocation: RANDOMIZED
• Masking: DOUBLE
• Who Masked: PARTICIPANT, INVESTIGATOR
• Purpose: BASIC SCIENCE
• Intervention Model: PARALLEL
• Sponsor Type: OTHER
• Responsible Party: PRINCIPAL INVESTIGATOR
• PI Title: Professor

Study Record Dates

• First Submitted: May 5, 2024
• First Posted: May 8, 2024
• Study Start: January 7, 2024
• Primary Completion: June 12, 2024
• Study Completion: June 20, 2024
• Last Updated: August 14, 2024

Record last verified: 2024-08

Data Sharing

• IPD Sharing: Will not share

Locations

CN (1)